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Abstract Changes in membrane expression of sodium-depen- 
dent glucose transporter (SGLTI) and glucose transporter 
isoform (GLUT2) protein have been implicated in the increased 
intestinal glucose transport in streptozotocin-diabetes. The 
possible involvement of GLUT1 in the transport response, 
however, has not previously been studied. Using confocal 
microscopy on tissue sections and Western blotting of purified 
brush border membrane (BBM) and basolateral membrane 
(BLM), we have examined enterocyte xpression of GLUTI in 
untreated and in 1 and 21 day streptozotocin diabetic rats. In 
control enterocytes, GLUT1 was absent at the BBM and 
detected at low levels at the BLM. Diabetes resulted in a 4- to 
5-fold increased expression of GLUT1 at the BLM and the 
protein could also be readily detected at the BBM. Insulin 
treatment of diabetic rats increased GLUT1 level at the BBM 
but was without effect on expression of the protein at the BLM. 
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I. Introduction 
GLUT1 and to determine the effects of early (1 day) and 
longer term (21 day) streptozotocin-induced diabetes on ex- 
pression of the protein. Insul in-treatment or fasting of dia- 
betic rats was also carried out in order to assess the impor- 
tance of changes in plasma glucose concentrat ion on 
expression of GLUT1.  
2. Materials and methods 
2.1. Animals 
Diabetes was induced by a single tail vein injection of streptozoto- 
cin (65 mg/kg, dissolved in pH 4.5 citrate buffer) into male Sprague- 
Dawley rats (initial weight 220-250 g) with the animal under light 
ether anaesthesia. Animals were allowed free access to a standard 
maintenance diet prior to their use 1 or 21 days later. Some 1 day 
diabetic animals were given Actrapid insulin (8 U subcutaneously, 
Novo Industries, Denmark) 2 h before use whilst some 21 day dia- 
betics were fasted 24 h before use but had free access to water. For 
removal of tissue, rats were anaesthetised with pentobarbitone sodium 
(Sagatal, May and Baker, 90 mg/kg i.p) and 5 cm of jejunum (begin- 
ning 10 cm from the ligament of Trietz) was removed for confocal 
microscopy and a further 20 cm for preparation of enterocyte mem- 
branes. Blood samples were then obtained by cardiac puncture and a 
glucose oxidase method was utilised for assay of the sugar in plasma. 
Experimental diabetes mellitus is associated with increased 
intestinal sugar transport  and both the BBM and BLM have 
been implicated in this transport  upregulation [1 3]. Recent 
studies have found raised enterocyte l vels of SGLT1 [4,5] and 
the facilitated transporter GLUT2 [5] in streptozotocin (STZ)- 
treated rats and increased expression of these proteins are now 
known to be involved in the enhanced glucose transport  at the 
BBM and BLM, respectively. 
GLUT1 was the first facilitated glucose transporter to be 
identified and characterised. It is expressed in a wide variety 
of cell types and is important  in mediating lucose transport  
across erythrocyte and endothelial membranes. Although the 
protein is found in certain transport ing cells e.g. renal prox- 
imal tubule and Caco-2 cells [6,7], there is, to date, no evi- 
dence for its expression in normal  small intestinal epithelium 
[8]. In the present study we have used confocal immunofluo- 
rescence microscopy of rat jejunum, together with Western 
blotting of BBM and BLM prepared from intestinal mucosa, 
in order to examine the normal enterocyte distribution of 
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2.2. Preparation of membrane vesicles 
Brush border and basolateral membranes were prepared using a 
previously described method with some modifications [9]. Jejunal mu- 
cosal scrapings were suspended in hypotonic buffer (in mM: 50 man- 
nitol, 2 HEPES, pH 7.1) and homogenised for 2X 30 s using an Ultra 
Turrax homogeniser (Janke and Kunkel, Germany) at full speed. This 
homogenate was centrifuged at 2500xg for 15 min and the super- 
natant centrifuged further (20 min at 20 500xg). This step produces a
double precipitate consisting of a white fluffy upper pellet and a hard 
brown lower pellet. The upper layer was used to purify BLM and 
could be easily removed by gentle swirling following the addition of 
5 ml resuspension buffer containing (mM) 300 mannitol, 20 HEPES, 
0.1 MgSO4, 0.5 PMSF and 100 U/ml aprotinin. The pellet was resus- 
pended with 6 strokes in a hand-held homogeniser and was layered 
onto a 30%140% sorbitol density gradient. Following centrifugation at
70000×g for 1 h the cloudy band at the 30%/40% interface was 
removed, diluted with resuspension buffer, and centrifuged for a 
further 20 min at 100000xg to obtain the basolateral pellet. 
For preparation of BBM, the hard brown pellet obtained as de- 
scribed above was resuspended in the resuspension buffer using a 
hand-held homogeniser. The homogenate was diluted to a final vol- 
ume of 60 ml with the same buffer and MgC12 (final concentration 10 
raM) and stirred on ice for 20 min. Following centrifugation at 
3000xg for 10 min, the resulting supernatant was centrifuged for a 
further 30 min at 27000xg to obtain the brush border pellet. All the 
above steps were performed at 4°C. 
BBM and BLM preparations were resuspended in the resuspension 
buffer described above to a protein concentration of 3 6 mg/ml. The 
activities of sucrase and alkaline phosphatase in the initial homoge- 
nate and BBM suspensions were determined [10,11] together with 
Na+,K+-ATPase activity [12] for the BLM preparation in order to 
calculate nrichment values for these enzymes in the membrane pre- 
parations. 
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Fig. 1. Confocal immunofluorescence images showing the localisation of GLUT1 in non-diabetic and diabetic jejunum. (A) Control section in- 
cubated with non-specific rabbit IgG in place of anti-GLUT1 antibodies. (B) GLUT1 in non-diabetic jejunum. Low magnification image show- 
ing immunostaining over the entire villus length. Note the widespread intracellular distribution of GLUT1 and the lack of Goblet cell staining 
(arrow). (C,D) 1 and 21 day diabetic jejunum, respectively, showing increased expression of GLUTI.  Scale bars=100 lam 
2.3. Western blotting 
Antiserum against GLUT1 was produced by immunising a rabbit 
with a synthetic peptide corresponding to residues 477-492 of rat 
GLUTI,  conjugated via an additional N-terminal cysteine residue to 
ovalbumin. Peptide-specific antibodies were affinity purified by pas- 
sage of the antiserum through a column of peptide immobilised on 
Sulfolink gel (Pierce), followed by elution in 50 mM diethylamine-HC1 
and dialysis into PBS. For Western blotting, membranes from control 
animals (20 ~tg) or diabetics (10 ~tg) were solubilised in Laemmli 
sample buffer [13] containing 1% SDS and electrophoresed on 10% 
SDS polyacrylamide gel. Proteins were then transferred from the gel 
to nitrocellulose filters by electrophoretic blotting for 1 h at a constant 
voltage of 100 V using a Bio-Rad Mini Trans-Blot Cell. Non-specific 
protein-binding sites on the filters were blocked by incubation for 2 h 
at room temperature with TTBS buffer (pH 7.5) containing (mM) 20 
Tris, 500 NaC1, 0.2% Tween 20, with the addition of 5% fat-free milk 
powder. Filters were next incubated overnight at room temperature 
with 1 ~g/ml affinity purified anti-GLUTl antibodies, in TTBS con- 
taining 1% fat-free milk powder. They were then washed (3 X 15 min) 
in TTBS, incubated for 2 h at room temperature with sheep anti- 
rabbit IgG conjugated to horseradish peroxidase, and finally washed 
again with TTBS (3 x 30 min). Bound antibodies were then detected 
using a chemiluminescence detection procedure (Boehringer Mann- 
heim, Germany) according to the manufacturer's instructions. 
For quantitation of the relative amounts of GLUT1 protein, X-ray 
films were scanned using a Scanmaster III Densitometer (Howtek, 
USA) and images were analysed using Quantity One v4.0 software. 
Preliminary work using known levels of GLUT1 protein on blots 
revealed a linear relationship between the intensity of chemilumines- 
cence and the amount of GLUTI present (data not shown). 
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Fig. 2. Higher magnification confocal immunofluorescence images showing localisation of GLUT1 in non-diabetic (A) and 1 and 21 day dia- 
betic jejunum (B and C, respectively). Note faint basolateral membrane staining of enterocytes in (A) in addition to intracellular staining. (B,C) 
Show increased intracellular expression of GLUT1, together with clear brush border (solid arrows) and basolateral membrane staining (open 
arrows). Also evident is dense staining in the peri-nuclear regions of enterocytes (*). Scale bar=20 ~tm 
2.4. Immunofluorescence microscopy 
Jejunal segments were flushed through with PBS and cut into por- 
tions 0.5 cm in length. These were fixed overnight at 4°C in PBS 
containing 4% paraformaldehyde and then transferred to PBS con- 
taining 7% sucrose and 0.1% sodium azide. Tissue was equilibrated in 
this solution overnight at 4°C and then embedded in OCT and frozen 
in liquid nitrogen cooled isopentane. Cryostat-cut sections (8 ~m 
thick) were placed on Vectabond coated glass slides and stored at 
4°C in PBS. 
For immunostaining, slides were incubated for 90 mins in PBS 
containing 3% BSA and then overnight at 4°C with the affinity puri- 
fied anti-GLUT1 antibody (20 Ixg/ml in PBS with 1% BSA). Sections 
were then washed (3 x 10 min) in PBS and incubated for 1 h at room 
temperature with a 1:100 dilution (in PBS with 1% BSA) of FITC- 
conjugated goat anti-rabbit IgG (Sigma). Sections were finally washed 
(3x 10 min) in PBS, mounted in Vectashield and finally visualised 
using a Leica Confocal Laser Scanning Microscope. 
2.5. Statistics 
Results are given as mean + S.E.M. Differences between means were 
evaluated by a Student's t-test and considered significant at p < 0.05. 
3. Results 
Streptozotoc in- t reated animals were hyperglycaemic (plas- 
ma glucose concentrat ion,  in mM:  control ,  10.8_+0.2; 1 day 
STZ, 34.4 + 2.9; 21 day STZ, 41.9 + 3.0). Insul in t reatment  for 
2 h reduced glucose level in 1 day diabetic animals to 8.6 + 0.5 
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mM whilst an overnight fast lowered plasma glucose concen- 
tration in 21 day diabetics to 11.2+ 1.3 mM. 
Confocal immunofluorescence microscopy of non-diabetic 
rat jejunum revealed a widespread intracellular distribution 
of GLUT1 (Fig. 1B). Staining was greatest in the lower/mid- 
dle two thirds of the villi with the upper villus showing re- 
duced expression of the protein. Staining was absent from the 
goblet cells (arrow). Staining was not seen using non-specific 
rabbit IgG instead of the anti-GLUT1 antibodies (Fig. 1A). 
Increased expression of GLUT1 was evident in jejunal sec- 
tions from 1 and 21 day STZ-treated rats (Fig. 1C and D, 
respectively). As with non-diabetic villi, the diabetic villi show 
highest expression of GLUT1 in the lower two thirds of the 
villi, with lower expression in the tips of the villi. The speci- 
ficity of GLUT1 staining of non-diabetic and diabetic jejunum 
was assessed by prior absorption of the antibody with the 
GLUT1 immunising peptide, which completely eliminated 
the signal seen (data not shown). 
Higher magnification confocal immunofluorescent images 
of non-diabetic rat jejunum revealed low, though detectable 
levels of GLUT1 at the BLM, in addition to intracellular 
GLUT1. It was possible to discern increased basolateral 
(open arrow) and brush border membrane (solid arrow) 
GLUT1 expression 1 and 21 days after treatment with STZ 
(Fig. 2B and C, respectively), as would be expected from the 
Western blot results described below. In addition, to the gen- 
erally increased GLUT1 staining throughout he cytoplasm, 
STZ treatment also specifically induced the expression of 
GLUT1 in the vicinity of the nuclei (*) (Fig. 2B,C). 
BBM preparations used for Western blotting were enriched 
16-18- and 10~13-fold for sucrase and alkaline phosphatase, 
respectively, compared to the homogenate, but showed no 
enrichment of Na+,K+-ATPase. BLM vesicles were enriched 
9 14-fold in Na+,K+-ATPase but not for the two BBM en- 
zymes. Diabetes was without effect on enzyme enrichments. 
Western blotting of membranes for GLUTI revealed clearly 
defined bands at an Mr of 54 000 (Fig. 3) in accordance with 
the apparent Mr of this protein in other tissues [14]. The 
bands migrated with the same mobility as that of purified 
human erythrocyte GLUT1. Specificity of the antibody was 
shown by complete limination of the bands on Western blots 
by prior absorption of the antibody with the immunising 
GLUT1 peptide (results not shown). Quantitation of the 
bands revealed that BLM levels of GLUT1 were 78.6 and 
387.1°/,, higher at 1 and 21 days, respectively, after STZ 
(ranges: control, 0.86-8.34; 1 day, 1.30-12.79; 21 day, 3.43- 
54 Q ii 
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Fig. 3. Western blot detection of GLUT1 in basolateral membranes 
(lanes 1,3,5) and brush border membranes (lanes 2,4,6) prepared 
from control rats (lanes 1,2) and 1 day (lanes 3,4), and 21 day 
(lanes 5,6) diabetic rats. 20 gg protein was applied per lane. Lane 
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Fig. 4. Quantification of GLUT1 in BBM (open bars) and BLM 
(striped bars) prepared from jejunal mucosa of control, 1 d and 21 
d diabetic rats, 2 h insulin treated 1 d diabetic rats and overnight 
fasted 21 d diabetic rats. Results were obtained by densitometry of
Western blots and are means (arbitrary units) + SEM for 4-10 mem- 
brane preparations. *p<0.02, **p<0.005 compared to control; 
+p<0.005 compared to 1 d diabetic; p<0.02 compared to 21 d 
diabetic. 
30.0 a.u.), although the increase only reached statistical sig- 
nificance after 21 days (p < 0.02 compared to control) (Fig. 4). 
These results confirm the diabetic pattern of GLUT1 expres- 
sion detected by immunofluorescence. GLUT1 expression at 
the BBM was increased by 200.8% (p<0.02) and 810.2% 
(p < 0.005) after 1 and 21 days treatment with streptozotocin 
respectively (ranges: control, 0.494).83; 1 day, 0.904.61; 21 
day, 4.81-13.94 a.u.). Insulin treatment of 1 day diabetics 
markedly enhanced BBM and BLM levels of GLUT1 whilst 
overnight fasting of 21 day diabetics was without significant 
effect on expression of the transporter at the BBM but re- 
duced by 53%, GLUT1 expression at the BLM. 
4. Discussion 
Upregulation of intestinal glucose transport during experi- 
mental diabetes has been widely reported and the response 
involves enhanced epithelial expression of the sodium-depen- 
dent transporter, SGLT1, at the BBM and the facilitated 
transporter GLUT2 at the BLM [1-3]. The effects of diabetes 
on enterocyte expression of GLUT1 have not previously been 
studied, presumably because of the reported absence of this 
protein in enterocytes from non-diabetic animals [8]. GLUT1 
is, however, expressed in Caco-2 cells, a colonic cell line which 
displays enterocyte-like properties [7]. 
Results from the present study show that the villus distri- 
bution of GLUT1 was similar to that reported for the other 
two enterocyte transporters, GLUT2 and SGLT1 [5]. In all 
cases, the progressive maturation of cells during their migra- 
tion along the villus results in maximal expression of transport 
protein in the mid-villus region. Transporter levels at the vii- 
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lus tip are generally lower than the mid-villus because of en- 
terocyte senescence and desquamation. 
The most important feature of our study is the finding that 
diabetes results in expression of GLUT1 at the brush border 
whilst, at the same time increasing levels of the protein at the 
BLM. It is likely that the very low density of GLUT1 detected 
on Western blots of non-diabetic BBM were a consequence of
slight contamination with BLM, which is inevitable, even in 
purified membrane preparations. However, such contamina- 
tion cannot explain the large elevation in GLUT1 levels seen 
in BBM from diabetic animals, since diabetes was without 
effect on the purity of either BBM or BLM membrane frac- 
tions as assessed using marker enzymes. Moreover, the results 
of confocal microscopy sections were unequivocal (Fig. 2). 
The finding that GLUT I -mRNA is below the level of detec- 
tion in enterocytes from non-diabetic rats [15] suggests tran- 
scriptional control of GLUT1 expression in diabetes. How- 
ever, studies of mRNA levels in diabetic rats will be 
required to confirm this point. Although there is a growing 
body of evidence that diabetes alters the membrane distribu- 
tion of GLUT2, another facilitated glucose transporter found 
at the enterocyte BLM, [16,17], our present work presents the 
first immunocytochemical evidence for the targeting of glu- 
cose transporters to the BBM in this condition. 
The widespread cytoplasmic distribution of GLUT1 is not 
seen with other enterocyte facilitated glucose transporters. 
However, a cytoplasmic localisation for a plasma membrane 
protein that cycles through the endocytic ompartment is to 
be expected. Indeed, intense intracellular vesicular staining for 
GLUT1 in BHK cells, particularly in the perinuclear region, 
has been reported and the transporters move from this com- 
partment to the cell surface in response to a variety of stimuli 
including metabolic stress [18]. 
The precise role of enterocyte GLUT1 in diabetes and its 
function in relation to other glucose transporters present at 
the BBM and BLM are unknown. However, enhanced mem- 
brane expression of GLUT1 in diabetes will result in greater 
facilitated glucose transport at the BLM and increased phlor- 
izin-insensitive (non SGLTl-mediated) glucose uptake at the 
brush border, both of which are a feature of the disease 
[1,2,19,20]. As such, increased enterocyte GLUT1 expression 
in diabetes will contribute to postprandial hyperglycaemia. 
The signals which influence GLUT1 expression and its sub- 
cellular localisation are unknown. Although it has been shown 
that insulin rapidly stimulates translocation of GLUT1 to the 
plasma membrane in other cell types [21] and, in the longer 
term, enhances expression of the protein [22], the differential 
effects of insulin treatment and fasting of diabetic animals, 
both of which normalise plasma glucose levels, imply that 
alterations in blood levels of neither insulin nor glucose are 
responsible for the changes in expression of GLUT1 at the 
BBM and BLM. A possible humoral mediator is pancreatic 
glucagon which is known to increase BBM and BLM sugar 
transport [9] and which is secreted in increased amounts dur- 
ing diabetes. The hormone may act by increasing the produc- 
tion of cAMP within enterocytes and in this context it is of 
interest hat experimentally raised cytosolic levels of cAMP 
promote enterocyte sugar transport [23]. cAMP has also 
been implicated in the regulation of glucose transporter ex- 
pression in other cell types [24]. Gaining an understanding of 
the extracellular factors which regulate the expression of 
GLUT1 will clearly be of major importance in elucidating 
the mechanisms by which enterocyte glucose transport is al- 
tered in diabetes. 
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